394 related articles for article (PubMed ID: 28832384)
1. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
2. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
3. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
5. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
6. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
7. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
8. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
9. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
[TBL] [Abstract][Full Text] [Related]
12. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Toms SA; Kim CY; Nicholas G; Ram Z
J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
[TBL] [Abstract][Full Text] [Related]
13. Progress and prospect in tumor treating fields treatment of glioblastoma.
Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
[TBL] [Abstract][Full Text] [Related]
14. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
15. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
16. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
17. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
[TBL] [Abstract][Full Text] [Related]
18. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Ballo MT; Conlon P; Lavy-Shahaf G; Kinzel A; Vymazal J; Rulseh AM
J Neurooncol; 2023 Aug; 164(1):1-9. PubMed ID: 37493865
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2021; 11():671972. PubMed ID: 34692470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]